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 Designer peptide delivery systems for gene 
therapy 
 Abstract :  Gene therapy has long been hailed as a revo-
lutionary approach for the treatment of genetic diseases. 
The enthusiasm that greeted the harnessing of viruses for 
therapeutic DNA delivery has been tempered by concerns 
over safety. These concerns led to the development of 
alternative strategies for nucleic acid delivery to cells. One 
such strategy is the utilization of cationic peptides for the 
condensation of therapeutic DNA for delivery to its target. 
However, success of DNA as a therapy relies on its delivery 
to the nucleus of target cells, a process that is complicated 
by the many hurdles encountered following systemic 
administration. Non-viral peptide gene delivery strategies 
have sought inspiration from viruses in order to retain 
DNA delivering potency, but limit virulence. This review 
summarizes the progression of peptide-based DNA deliv-
ery systems, from rudimentary beginnings to the recent 
development of sophisticated multi-functional vectors 
that comprise distinct motifs with dedicated barrier eva-
sion functions. The most promising peptides that achieve 
cell membrane permeabilization, endosomal escape and 
nuclear delivery are discussed. 
 Keywords:  biological barriers;  DNA;  gene therapy;  non-
viral;  peptide. 
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 Introduction 
 Since the inception of gene therapy in 1972, much progress 
has been made to underpin its present-day potential as a 
treatment for diseases of genetic origin  (1) . The capacity 
for foreign DNA to induce functional changes to the host ’ s 
intracellular machinery is well established. However, DNA 
can only exert its therapeutic potential if delivered to the 
nucleus of the target cells. The major stumbling block in 
the development of gene therapies has been the dearth of 
efficacious delivery systems  (2, 3) . 
 Viruses are naturally adept at hijacking the host cells ’ 
machinery to enable their own proliferative agenda. Tai-
loring of known human viruses as potential gene deliv-
ery vectors therefore became the initial focus of research 
within the field  (4) . However, despite attempts to remove 
the pathogenic components of the viral apparatus, pro-
gress of these vectors has been thwarted due to safety 
concerns stemming from their use, and indeed patient 
perception  (5) . Non-viral based strategies manage to over-
come some of the safety concerns associated with the use 
of viral vectors but have, as of yet, failed to match the effi-
cacy of their viral counterparts  (6) . The use of naturally 
occurring and/or synthetic peptides whose designs are 
based upon viral sequences, therefore present an attrac-
tive alternative for nucleic acid delivery. Multi-functional 
peptide-based nanoparticles comprising distinct motifs 
with specific functionalities designed to overcome the 
extra- and intra-cellular barriers could, in theory, be used 
for safe and efficient gene delivery  (7) . Here we discuss 
the various hurdles that a gene delivery vector must over-
come, functional peptides that are capable of facilitat-
ing their circumvention, and strategies to combine these 
peptides to develop effective bio-inspired gene delivery 
vectors. 
 Barriers to gene therapy 
 The ideal gene delivery system should be non-toxic, bio-
degradable, targeted, non-immunogenic and easily manu-
factured. In order to design such a peptide delivery system, 
numerous biological barriers must be understood. Follow-
ing systemic injection, prospective peptides must firstly 
protect the therapeutic gene from the action of mononu-
clear phagocytes, complement and reticulo-endothelial 
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systems, all of which results in rapid clearance from the 
body  (8) . Additionally the peptide must be able to extrava-
sate from the circulation, pass through the fibrous extra-
cellular matrix and reach the target tissue whilst ensuring 
any off-target effects are limited  (9) . Once the therapeutic 
reaches the target site, the peptide has to penetrate the 
cell membrane in order to deliver the genetic cargo. The 
mechanism of internalization has a consequential impact 
on its intercellular fate thereafter. 
 Peptides can be internalized by two main pathways: 
A) Endocytic or energy dependent pathways (clathrin-
mediated, caveolae/lipid raft-mediated, clathrin and 
caveolae-independent endocytosis and macropinocyto-
sis) and 2) direct penetration or energy independent path-
ways (e.g., inverted micelle model, pore formation, carpet 
model) ( Figure 1 )  (10) . If internalization is by endocytosis, 
as is predominantly the case, the objective is to escape 
the endosome, otherwise the genetic material will be 
degraded and expelled via a lysosome  (11) . If endosomal 
escape is successful then the DNA must be delivered to the 
nucleus where it can finally exact a sustained therapeutic 
effect  (12) . Each of these barriers must be overcome oth-
erwise failure of the therapy is inevitable. Consequently, 
an in depth knowledge of these barriers is fundamental to 
effective peptide design. 
 Nucleic acid condensation 
 The capacity to effectively bind to and condense DNA into 
stable nanoparticles is essential in order to protect the 
cargo from enzymatic degradation in the systemic circula-
tion and in the cytoplasm  (13, 14) . The use of condensing 
motifs can significantly enhance stability in vivo, protect 
DNA from the action of lytic enzymes, and ensure an 
appropriate nanoparticle size (  <  200 nm) to facilitate cel-
lular uptake  (15, 16) . 
 Gratton et  al.  (17) employed a technique known as 
particle replication in non-wetting templates (PRINT) to 
define the significance of particle size, shape and surface 
charge on non-specific cellular uptake. In the study a 
clear correlation is evidenced between particle size and 
the extent of cellular uptake. Particles with a size   >  1 
micrometer exhibited significantly reduced internali-
zation kinetics compared to those that occur within the 
nanometer scale. However, size, although significant, was 
not the only defining characteristic with regard to cellu-
lar uptake profiles of PRINT particles. Both surface charge 
and shape were also shown to be important determinants 
of internalization, with rod-shaped, high aspect-ratio 
PRINT particles carrying a positive zeta potential the most 
readily internalized. These, therefore, represent the fun-
damentals towards which scientists involved in the field 
of particle design should strive. 
 The common feature shared by all DNA condensing 
peptides is their cationic nature, and size-suitability in the 
condensed form ( Table 1 ). One of the first polypeptides, 
Poly-L-Lysine (PLL) consisted of biodegradable repeated 
lysine residues that effectively condensed DNA; endo-
somal entrapment limited PLL ’ s ability to successfully 
deliver genetic material  (18) . Subsequently numerous 
studies have examined the merits of using either lysine- or 
arginine-based peptides for gene delivery, with the more 
compelling evidence firmly supporting arginine. Arginine 
binds to the DNA in milliseconds  (19) , has a stronger affin-
ity for the phospholipid phosphatidylserine (Ptd-Ser) on 
the inner leaflet of membranes  (20) , and is a superior inter-
nalizer to oligolysines  (21) . Furthermore, recent studies by 
Mann et  al.  (22) demonstrated that block distribution of 
arginine R 5 H 7 R 4 results in stronger condensation of DNA 
but that the addition of histidine residues either by R 9 H 7 or 
H 4 R 9 H 3 were less effective at condensation but much better 
at releasing the genetic cargo giving a higher transfection. 
These studies support those of Hatefi ’ s group, who sug-
gested that vector architecture of the amino acid sequence 
is critical, and that clusters of lysine and histidine (KKKH-
HHHKKK) were superior to interspersed (KHKHKHKHKK) 
sequences  (23) . As a cationic residue, histidine not only 
condenses nucleic acids to an extent but perhaps more 
importantly also facilitates the release of the genetic cargo 
from the endosome via the proton sponge effect  (24) . 
 Other arginine-rich sequences exist in nature such as 
protamine, which plays a key role during spermatogenesis 
by replacing histones, thus ensuring tight condensation 
of the DNA  (25) . The Mu peptide (MRRAHHRRRRASHR-
RMRGG) is a 19 mer, arginine-rich peptide first identi-
fied and isolated from the adenovirus core complex in 
1976  (26) . The Mu peptide has been shown to consist-
ently bind DNA into small, stable nanoparticles, which 
has led to its application in a number of peptide-based 
delivery systems  (27, 28) . Nevertheless peptides such 
as protamine and Mu remain uni-functional and so fre-
quently they are imported into multi-functional systems 
to take advantage of their DNA binding characteristics. 
For example protamine has been utilized as the core 
DNA binding component of a multifunctional envelope 
type nano device (MEND) incorporating the fusogenic 
peptide GALA and the nuclear localization signal (NLS) 
maltotriose which boosted transfection efficiency 15.8-
fold higher than that of the commercially available in 
vivo-jet-PEI ™ -Gal  (29) . 
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 Figure 1:   Schematic representation of endocytic (A, B and C) and direct penetration (E, F and G) mechanisms of internalization. (A) 
Clathrin-mediated endocytosis: Peptides are engulfed in clathrin-coated vesicles. Clathrin coating is shed prior to fusion with acidic, late 
endosomes. (B) Caveolea-mediated endocytosis: Peptides are engulfed in caveolae-coated vesicles and transported via microtubules to 
pH neutral caveosomes. (C) Macropinocytosis: Protrusive flaps of the cellular membrane non-selectively engulf extracellular material. (D) 
Inverted micelle model: Inverted micelles are generated upon interaction of peptides with negatively charged phospholipids. Peptides 
remain in a hydrophilic environment as they transverse the hydrophobic core of the lipid bilayer. (E) Carpet model: Peptides  “ carpet ” the 
surface of the membrane imposing curvature strain and membrane collapse. (F) Pore formation model: Hydrophobic residues insert into the 
phospholipid core resulting in transient pore formation. 
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 Table 1 :   DNA condensing motifs. 
Peptide Sequence Origin Reference 
Poly-L-lysine (PLL) (L) n Synthetic  (18) 
R 5 H 7 R 4 RRRRRHHHHHHHRRRR Synthetic  (22) 
K 3 H 4 K 3 KKKHHHHKKK Synthetic  (23) 
Protamine sulfate RSSSRPVRRRRRPRVSRRRRRRGGRRRR Salmon sperm  (25) 
Mu ( μ ) MRRAHHRRRRASHRRMRGG Adenovirus core complex  (26) 
Tat (48 – 60) GRKKRRQRRRPPQ HIV-1 transactivator  (48) 
Oligoarginine (R) n Synthetic  (56) 
 Karjoo et  al.  (30) reported transfection efficiencies 
(  >  95%) in ovarian cancer SKOV3 cells with a viral mimetic 
nanoparticle system designated THG/Mu-PEG5K. The THG 
biopolymer, which consists of a targeting peptide (T), four 
repeating units of histone (H) and the fusogenic peptide 
GALA (G), was mixed at a ratio of 8:8 with the covalently 
bonded Mu-PEG5K to form stable nanoparticles with 
pEGFP-N1  (30) . 
 When selecting a peptide sequence it must be noted 
that a fine balance is required between protecting the DNA 
from extracellular degradation, achieving favorable phar-
macokinetics and ensuring effective intracellular release. 
Indeed the very characteristics that make cationic pep-
tides powerful condensers of nucleic acids may also det-
rimentally affect nanoparticle biodistribution in vivo and 
cytoplasmic release of DNA. Whilst condensation with 
cationic peptides can dramatically reduce interaction 
of DNA with enzymatic elements in vivo, peptides too, 
particularly highly cationic, arginine-rich peptides, are 
susceptible to rapid clearance from the body and degra-
dation by proteolytic plasma enzymes  (31) . Such problems 
may be overcome by functionalization with polyethylene 
glycol (PEG)  (32) . However, modification in this way has 
been shown to adversely affect intracellular kinetics  (33) . 
This problem may, in turn, be overcome by the use of 
sheddable PEG coatings. Zhu et al. (34) reported improved 
tumor accumulation and tumor-specific cleavage of a self-
assembly block copolymer (PEG-pp-PEI-PE) due to the use 
of an MMP2 labile linker for PEG . 
 Therefore, with regard to the method of nucleic acid 
condensation, there is much to consider. And this is only 
the first step in a complex process. 
 Membrane destabilization 
 Traversing the cellular membrane is the next critical 
step for successful gene delivery. Cell-penetrating pep-
tides (CPPs) are a class of peptides that can facilitate the 
permeabilzation of biological membranes. Endocytosis 
is the predominant mechanism of membrane transloca-
tion by CPPs with subsequent entrapment in the endo-
some, acidification and degradation of the genetic cargo 
unless escape to the cytosol can occur  (35) . Alternatively if 
CPPs enter the cell via direct membrane translocation, the 
endosome is by-passed and the need for an escape mecha-
nism in the design of the peptide is circumvented. Eluci-
dation of the mechanisms by which specific peptides are 
internalized is therefore crucial to effective vector design. 
 In the literature, CPPs have been categorized either 
according to their origin as protein-derived, chimeric or 
synthetic; or, according to their amphipathic profile as 
primary amphipathic, secondary amphipathic or non-
amphipathic ( Table 2 ). Their designation as such depends 
largely on the specific amino acid engineering and physi-
ochemical properties of the peptide in question  (10) . 
Unsurprisingly arginine abundance is a common feature 
of CPPs, characterized by the presence of the guanidine 
head group, thus facilitating formation of strong biden-
date hydrogen linkages with anionic components of the 
cell membrane  (36 – 38) . There is to date no consensus 
on the precise mechanism of cellular internalization of 
 arginine-rich CPPs. However the degree and manner of 
initial interaction with the cell surface membrane ulti-
mately dictates the eventual pathway of internalization 
and is generally recognized as being the first step of the 
CPP internalization process. 
 In a landmark study, cell surface activity and inter-
nalization was examined using Penetratin (RQIKI WFQNR 
RMKWK K-amide), a 16 amino acid peptide derived from 
the third helix of the Antennapedia homeodomain, PenArg 
(RQIR IWFQ NRRM RWRR-amide) and PenLys (KQIK IWFQ 
NKKM KWKK-amide)  (39) . Studies revealed that the levels 
of internalization with PenArg were 10 times higher than 
those seen with PenLys, indicating that arginine inter-
acted more strongly with phospholipid membranes than 
lysine.  Å mand et  al. (39) then went on to quantify the 
relationship between strength of CPP interaction with cell 
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membrane and degree of cellular internalization, demon-
strating conclusively an almost linear correlation between 
the two factors and verifying the previously unsubstanti-
ated supposition that strength of interaction with the cell 
membrane is the crucial first consideration in deciphering 
CPP mechanism of internalization . Self-stimulated macro-
pinocytosis was also shown to be the primary mechanism 
of membrane translocation for the PenArg CPP. Yet the 
cellular uptake of a chimera hybrid consisting only of D- 
and L-arginine isomers has been shown to be via direct 
membrane translocation following inhibition of endocytic 
pathways by both physical and pharmacological means 
 (40) . Direct translocation was further confirmed when the 
transmembrane potential was eliminated resulting in a 
drastic reduction in chimeric oligoarginine in the cytosol. 
Transmembrane potential is therefore another critical 
factor to consider in the translocation of guanidium-rich 
peptides  (41) . 
 The differences in transmembrane activity exhibited 
by arginine-rich CPPs can also be related to the amphi-
pathic profile of the peptide  (42, 43) . For example the 
presence of two tryptophan (W) residues in the Penetra-
tin backbone has led to its designation as a secondary 
amphipathic peptide, described as such due to the distri-
bution of hydrophobic and hydrophilic charges on its sec-
ondary structure following interaction with phospholipid 
membranes  (44) . The presence, size and hydrophobic 
character of W has been shown to functionally enhance 
the internalization activity of CPPs primarily through 
improved anchoring of peptides to cell membranes  (45) . 
To what degree this amphipathic quality dictates the 
route of internalization is not clear. However, complete 
loss of function of Penetratin was observed following 
substitution of tryptophan (W6) for phenylalanine  (46) . It 
was then postulated that Penetratin followed a two-step 
model for internalization that involved initial electrostatic 
interaction followed by tryptophan-dependent membrane 
destabilization . The evidence is mounting that tryptophan 
therefore has a key role to play in the design of secondary 
amphipathic peptides. Indeed studies by Jafari et al. (47) 
demonstrated that replacing three leucine residues in the 
18 mer C6 peptide with tryptophan to give C6M1 not only 
increased peptide solubility and secondary helical struc-
ture but also reduced cytotoxicity and increased intracel-
lular uptake. Incorporation of tryptophan and leucine 
residues into modified Tat 48 – 60 markedly enhanced 
leakage from plasma membrane vesicles compared to 
those lacking a hydrophobic component  (48) . 
 Rydberg et  al.  (49) took the studies with CPPs one 
step further by examining the effect of arginine and tryp-
tophan positioning within the peptide. Results indicated 
that positioning 1 – 4 tryptophans at the N-terminus sig-
nificantly impaired efficacy; while cellular uptake was 
highest for the RWmix (RWRRWRRWRRWR), attributable 
to greater secondary amphipathicity afforded by equal 
spacing of the residues, cytotoxicity was lower in a RWR 
(RRRRWWWWRRRR) sequence that achieved greater 
accumulation in the cytoplasm and nucleus, aided by the 
non-endocytic uptake route  (49) . The positioning of the 
amino acid residues then becomes a critical factor with 
only the RWmix entering via endocytosis. Taken together 
it becomes apparent that when designing a peptide for 
nucleic acid therapeutics, the distribution of the selected 
residues can have a profound influence on the mechanism 
of uptake. 
 The effects of cargo and cell membrane composition 
on internalization are also key considerations that cannot 
be overlooked. The size and type of cargo, as well as the 
manner of binding to the CPP, can influence CPP trans-
location characteristics  (50 – 52) . Much information to 
this regard has been gleaned from the implementation of 
unilamellar vesicles as model membranes to analyze the 
 Table 2 :   Cell-penetrating peptides. 
 Peptide Sequence Origin Amphipathic designation Reference 
Protein derived Penetratin RQIKIWFQNRRMKWKK-amide Antennapedia homeodomain Secondary-amphipathic  (39) 
PenArg RQIRIWFQNRRMRWRR-amide Antennapedia homeodomain Secondary-amphipathic  (39) 
PenLys KQIKIWFQNKKMKWKK-amide Antennapedia homeodomain Secondary-amphipathic  (39) 
Tat (48 – 60) GRKKRRQRRRPPQ HIV-1 transactivator Non-amphipathic  (48) 
Chimeric TP 10 AGYLLGKINLKALAALAKKIL Galanin  + Mastoparan Primary-amphipathic  (52) 
Synthetic C6 RLLRLLLRLWRRLLRLLR Synthetic Secondary-amphipathic  (47) 
RWmix RWRRWRRWRRWR Synthetic Secondary-amphipathic  (49) 
RWR RRRRWWWWRRRR Synthetic Non-amphipathic  (49) 
Olioarginine (R) n Synthetic Non-amphipathic  (56) 
 Oligolysine (R) n Synthetic Non-amphipathic  (56) 
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interaction of CPPs with lipid membranes. A recent pub-
lication by Vasconcelos et  al. (53) used large unilamel-
lar vesicles (LUVs) to delineate the relationship between 
peptide hydrophobicity and membrane perturbation char-
acteristics of sterylated analogues of Transportan 10. They 
demonstrate that the interaction between the peptide and 
its given cargo can have an important influence on CPP 
secondary structure and therefore internalization profiles 
 (53) . However, the use of liposomal models as a tool to elu-
cidate CPP mechanism of action is discouraged by some, 
who claim they do not adequately represent the environ-
mental complexity of live cells  (48) . 
 Cell membrane glycosiaminoglycan (GAG) content 
has also been cited as a crucial mediator of internali-
zation  (54,  55) . Naik et  al. (56) examined the effect of 
surface-bound and free GAGs on the permeabilization 
characteristics of R 16 and K 16 homo-peptides in live cells. 
Results found that DNA complexed with the R 16 peptide 
enter cells via non-endocytic and endocytic pathways, but 
that both are GAG independent. Complexes of DNA and 
the K 16 peptide enter primarily via an endocytotic pathway, 
and is dependent on GAG presence  (56, 57) . Subrizi et al. 
 (48) further challenged the role played by GAGs in cellu-
lar uptake, producing evidence that they actually inhibit 
movement of the Tat peptide across biological membranes 
in live cells. Indeed many of the methods used to analyze 
CPP  behavior exhibit a high degree of analytical variabil-
ity that only fuels the debate surrounding the mechanisms 
of cellular uptake  (36) . 
 Therefore until standardized methods are agreed 
amongst the field for evaluating the CPP phenomenon, 
correlations between peptide composition and cellu-
lar uptake will be difficult to elucidate. What is com-
monly accepted is that CPP permeabilzation occurs via 
two or more pathways and the propensity of any given 
CPP toward a particular pathway is highly variable and 
depends on a number of factors. These factors include CPP 
size, distribution of charge, hydrophobicity and peptide 
conformation, as well as considerations of cell membrane 
composition and cargo. These variables need to be accu-
rately accounted for in experimental design to ensure 
reproducibility and consistency of results. Once this is 
achieved peptides can be tailored to ensure maximal 
accumulation within the desired intracellular location. 
 Endosomal escape 
 Endocytosis is the primary mechanism for movement of 
extracellular material across biological membranes  (11) . 
Once endocytosed, the transported material is engulfed 
within an endosome. Lysosomes fuse with endosomes 
resulting in the acid degradation of the endosomal con-
tents. This presents a significant barrier to gene delivery, 
one that must be overcome in order for DNA to reach its 
site of action, namely the nucleus. Fusogenic peptides are 
a class of amphipathic peptides derived from the N-ter-
minal segment of the HA-2 subunit of the influenza virus 
hemagglutinin  (58) . The HA2 peptide (GLFGAIAGFIENG-
WEGMIDG) forms an  α -helix under acidic conditions and 
fuses with the endosomal membrane, enabling cargo 
delivery into the cytosol  (59) . At physiological pH, the lytic 
activity of the HA2 peptide is negligible, which confers a 
level of targeting for endosome of the target cell. This then 
renders HA2 peptide and subsequent derivatives suitable 
for systemic administration. 
 One of the first derivatives of the HA2 sequence was 
the 30 mer designer peptide GALA (WEAALAEALAEAL-
AEHLAEALAEALEALAA), characterized by a glutamic 
acid-alanine-leucine-alanine repeat  (60) . The maximum 
 α – helical conformation of GALA occurred at a pH 5 which 
gives rise to a hydrophobic face on one side of the peptide 
and a subsequent interaction with the endosomal mem-
brane. This results in pore formation and endosomal escape 
of the cargo to the cytosol. The repeating glutamic residues 
in GALA render it anionic and therefore ineffective for con-
densing and protecting nucleic acids. Nevertheless GALA 
has been utilized in several multi-functional systems as 
a discrete endosomal-disrupting motif. For example, the 
GALA peptide was incorporated into a biomimetic vector 
that also had four repeats of histone proteins to condense 
DNA, a targeting motif for HER2 and a cathepsin substrate 
that acts as an intracellular cleavage site  (61) . Studies dem-
onstrated that positioning GALA on the N-terminus of the 
multifunctional vector ensured fusogenic amphipathic 
activity. GALA has also been utilized in the R8-MEND system 
to significantly improve gene expression in the liver (618-
fold) in nanoparticles with a pDNA/PEI negative core  (62) . 
 In a bid to increase the functionality of GALA, 
Wyman et  al.  (63) substituted the negatively charged 
glutamic acid residues of GALA with positively charged 
lysine to produce the cationic peptide KALA (WEAK-
LAKALAKALAKHLAKALAKALKACEA), which not only 
retains its fusogenic activity but can also condense nega-
tively charged nucleic acids thanks to the positive charge 
conferred by the lysine. KALA has been utilized as an 
independent transfection agent alone and also to improve 
the activity of other delivery vehicles. KALA coating of 
PEG-g-PLL not only increased transfection efficiency but 
also displayed negligible toxicity compared to PEG-g-PLL 
alone  (64) . KALA has also been used to coat magnetic 
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mesoporous silica nanoparticles capped with PEI to 
deliver VEGF siRNA (M-MSN-siRNA@PEI-KALA) to not 
only reduce cytotoxicity but also significantly delay tumor 
growth in A549 lung tumors in vivo  (65) . 
 Given the superiority of arginine over lysine as 
previously discussed, McCarthy et  al.  (66) went on to 
create another cationic peptide termed RALA (WEAR-
LARALARALARHLARALARALRACEA) to deliver DNA. 
Studies demonstrated that the fusogenic activity of RALA 
remained pH-dependent, toxicity was reduced in vitro 
compared to a commercial agent and that cellular entry 
was via caveolin- and clathrin-mediated endocytosis. Fur-
thermore the RALA/pDNA nanoparticles retained activity 
following lyophilization with trehalose giving a suitable 
isotonic formulation for in vivo administration. Following 
systemic administration, gene expression was maximally 
observed in the lungs and liver  (66) . 
 A recent study carried out by Nouri et  al. (67) com-
pared the fusogenic activity of GALA, KALA and a number 
of other synthetic HA2-derived fusogenic peptides, INF7 
(GLFEAIEGFIENGWEGMIDGWYG)  (68) , H5WYG (GLFHAI-
AHFIHGGWHGLIHGWYG)  (69) and RALA, each coupled 
with four histone repeats and a targeting motif. Although 
GALA outperformed the other peptides in terms of both 
the percentage of cells transfected and the levels of green 
fluorescent protein expressed, H5WYG performed best in 
the hemolytic assay, suggesting that of the five fusogenic 
peptides investigated, H5WYG is superior at disrupting 
endosomal membranes. This result was not unexpected 
as the presence of an imidazole ring in H5WYG acts as a 
proton sponge, thus enhancing the pH-buffering capacity 
of the peptide. H5WYG has a pKa value of approximately 
6.0 and will be protonated at around pH 6. This prop-
erty therefore facilitates early escape from weakly acidic 
endosomes whilst remaining in an inactive conformation 
at physiological pH  (68) . It should be noted, however, that 
the contribution offered by improved buffering is cur-
rently debated, with some finding that improved buffering 
of polymer complexes at low pH may not always enhance 
endosomal escape  (70) . 
 Histidines have also been employed to improve TAT 
as a gene delivery vehicle. Although TAT is excellent at 
condensing DNA and traversing the cell membrane, it 
cannot escape the endosome, rendering it ineffective for 
gene delivery. However, Lo et  al. covalently added histi-
dine residues to the C-terminus of TAT and found that the 
addition of 10 residues resulted in a 7000-fold increase in 
gene expression  (71) . Further modifications included the 
addition of two cysteine residues to improve stabilization 
and an equal distribution of histidine to give C-5H-Tat-
5H-C which improved transfection a further 1000 fold  (71) . 
 It is important to note however, that the fusogenic 
activity of these peptides is a consequence of a pH-depend-
ent shift in their conformational status, occurring in the 
late endosome or upon fusion with a lysosome following 
clathrin-mediated endocytosis. Endocytosis by non-acidic 
pathways such as caveolae-mediated endocytosis and 
macropinocytosis will nullify the membrane lytic activity 
of fusogenic peptides, in which case entrapment within 
the endosome remains a major problem. Therefore, before 
employing a fusogenic peptide in any delivery system, due 
consideration must first be given to the mechanism of cel-
lular entry. 
 Nuclear import 
 Of all the barriers to gene delivery, nuclear import is by 
far the most challenging to overcome. The nucleus is 
enveloped by a highly impermeable double lipid bilayer 
known as the nuclear membrane  (72) . Movement across 
this membrane is regulated by highly restrictive nuclear 
pore complexes, interacting protein domains that form 
aqueous channels between the cell cytoplasm and the 
nucleoplasm. At their narrowest point these channels are 
a diameter of around 10 nm, allowing passive diffusion of 
ions and small proteins (  <  10 nm) into the nucleus. Move-
ment of larger molecules into the nucleus relies on nuclear 
localization signals (NLS), small peptide sequences that 
interact with components of the importin super family 
of proteins, which mediate macromolecular movement 
into the nucleus. The genetic cargo must be within close 
proximity to the nuclear membrane to enable binding to 
nuclear transport factors, a process that can be facilitated 
by components of the cell cytoskeleton, which coordinate 
movement of molecules through the  “ cytoplasmic sieve ” 
 (12) . The challenge is therefore to identify a NLS that can: 
1) Retain functionality by not binding to the genetic cargo 
that is to be delivered, 2) interact sufficiently with ele-
ments of the cytoskeleton to mediate accumulation of the 
genetic cargo around the outer membrane of the nuclear 
envelope and 3) bind specifically with importin adaptor 
proteins that arbitrate nuclear uptake. 
 Over the past number of decades many peptide NLSs 
have been identified for the purposes of active shut-
tling of DNA to the nucleus and their ability to enhance 
nuclear accumulation of cargo. However, despite numer-
ous attempts to improve transfection with non-viral 
vectors through the use of NLSs, nuclear accumulation 
in quiescent cells remains a significant barrier to success-
ful gene delivery  (73) . When selecting a NLS in peptide 
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design, the key factors that need to be considered are 1) 
NLS characteristics, 2) cellular characteristics and 3) cargo 
characteristics. 
 NLS characteristics 
 Classical NLSs, such as the REV peptide derived from 
HIV (RQARRNRRNRRRRWR) and the large tumor antigen 
of the simian virus 40 (SV40) (PKKKRKV) are short, 
basic peptides that interact with importin- α adaptor 
proteins to mediate transport to the nucleus. Kim et al. 
(74) recently demonstrated enhanced transfection when 
a cysteine-enriched SV40 derivative (GYGPKKKRKVGGC) 
was complexed with pLuc DNA before cationic liposome 
encapsulation. Several variants of the SV40 were tested, 
but only the C terminal disulfide homodimer resulted in 
improved efficiency and DNA release  (74) . The human 
mRNA-binding protein hnRNP M9 (GNYNNQSSNF-
GPMKGGNFGGRSSGPYGGGGQYFAKPRNQGGY) is an 
example of a non-classical NLS, which binds directly 
to importin- β without binding to importin- α adaptor 
proteins  (75) . The unordered M9 peptide is distinctly 
useful in multifunctional peptide systems because 
the lack of basic residues reduces interaction with the 
DNA cargo and therefore the NLS functionality remains 
intact. Canine et al.  (76) utilized the M9 NLS in a mul-
tifunctional biopolymer termed FP-DCE-NLS-TM where 
FP is a fusogenic peptide, DCE a DNA condensing and 
endosomolytic sequence and the TM a targeting motif. 
A truncated version FP-DCE-TM evoked negligible gene 
expression thus proving that the M9 NLS remained func-
tional in the biopolymer  (76) . 
 Cellular characteristics 
 The binding affinities of nuclear transport proteins 
to particular NLS is cell-type dependent. Gu et  al.  (77) 
characterized the nuclear import characteristics of the 
HIV-1 derived Rev peptide across different cell lines, 
with results suggesting that HeLa, U937 and THP-1 
cell lines employed transportin as the major transport 
receptor to rev, whereas in 293T, Jurkat or CEM cell lines, 
importin- β was the primary mediator of nuclear uptake. 
Intranuclear transport characteristics are also known 
to alter once cells become cancerous  (78, 79) . A trun-
cated form of importin- α has been found to lack a NLS 
binding domain in ZR-75-1 breast cancer cells, which 
would restrict the efficacy of any NLS operating on that 
pathway, e.g., SV40  (80) . 
 Cargo characteristics 
 Direct conjugation of the NLS to the DNA cargo has largely 
failed to significantly enhance gene expression  (12, 72) . 
In its uncondensed form, DNA is susceptible to degrada-
tion by cytoplasmic enzymes and movement through the 
densely packed cytosol is impeded due to the unordered 
state and size of uncondensed pDNA  (81, 82) . Use of cati-
onic condensing agents such as the core protein Vll of 
adenovirus type 2 or histones that contain inherent NLS 
have been shown to help overcome such issues  (83, 84) . 
However, more success has been derived from the conjuga-
tion of NLS to polycation binding proteins, thus reducing 
interference from cargo. Yi et al.  (85) reported a 200-fold 
enhancement in transfection efficiency of Tat conjugated 
to the NLS PKKKRKV-NH 2 (PV) compared to Tat/DNA com-
plexes alone. Furthermore, complexes formed by non-
specific electrostatic interaction (Tat/PV/DNA) showed no 
significant enhancement in transfection. Therefore with 
respect to peptide design it is better to covalently attach 
the NLS to the peptide and also ensure availability of the 
NLS to the importin proteins within the cytosol. 
 Conclusion 
 The phrase  “ from needle to nucleus ” is one that has 
been coined as the ideal in vector development for gene 
therapy. In reality however, the process is a stepwise one, 
with numerous hurdles that must first be overcome before 
the nucleus of target cells is reached. The purpose of this 
article is to identify peptides that can be utilized to help 
advance this agenda. 
 One criticism of peptide-based gene therapy might be 
the failure, thus far, to identify a single peptide sequence 
independently capable of highly efficient gene delivery. 
Progress therefore, relies on a multifaceted approach 
to nanoparticle design; one that involves collabora-
tion across various non-viral disciplines and one that is 
based on systematically addressing the biological barriers 
faced. Such a philosophy has led to the development of 
a variety of peptide-enhanced, multifunctional nanopar-
ticle systems, some of which have been referred to herein. 
Examples include the amelioration of polymers, lipids, 
micelles, chitosan and MENDs with peptides for improved 
gene delivery. For a comprehensive analysis of multi-
functional non-viral vectors in gene therapy the reader is 
referred to a recent review by Wang et al.  (86) . 
 Therefore, whether required for targeting, nucleic acid 
condensation, membrane destabilization, endosomal 
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escape or nuclear localization, peptides offer a wealth of 
promise when incorporated into multifunctional system 
designs such as these. 
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